Verastem to Present at the 29th Annual ROTH Conference
March 07 2017 - 7:00AM
Business Wire
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and
developing drugs to treat cancer, today announced that the company
will present at the 29th Annual ROTH Conference on Monday, March
13th at 4:00 p.m. PT at the Ritz Carlton in Dana Point, CA.
A live audio webcast of the presentation will be available on
the company’s website at www.verastem.com. An archived
presentation will be available for 90 days.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company
focused on discovering and developing drugs to improve outcomes for
patients with cancer. Verastem is currently developing
duvelisib, a dual inhibitor of phosphoinositide-3-kinase
(PI3K)-delta and PI3K-gamma, which has successfully met its primary
endpoint in a Phase 2 study and is currently being evaluated in a
Phase 3 clinical trial in patients with chronic lymphocytic
leukemia (CLL). Other clinical product candidates include focal
adhesion kinase (FAK) inhibitors defactinib and VS-4718, and dual
PI3K/mTOR inhibitor VS-5584. Defactinib is currently being
evaluated in three separate clinical collaborations in combination
with immunotherapeutic agents for the treatment of several
different cancer types, including pancreatic, ovarian and non-small
cell lung cancer, and mesothelioma. Verastem’s product candidates
seek to treat cancer by modulating the local tumor
microenvironment, enhancing anti-tumor immunity and reducing cancer
stem cells. For more information, please
visit www.verastem.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170307005389/en/
Verastem, Inc.Brian Sullivan, 781-292-4214Director,
Corporate Developmentbsullivan@verastem.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Sep 2023 to Sep 2024